Showing results (291-300 of 355) with videos related to

Sort By:
Pageof 36
Journal of the American College of Cardiology|August 30, 2022
Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection FractionJonathan W Cunningham, Muthiah Vaduganathan, Brian L Claggett, et al.
JAMA Cardiology|September 4, 2024
Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical TrialMatthew M Y Lee, Ahmad Masri, Michael E Nassif, et al.
European Heart Journal|November 20, 2024
Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney diseaseJohn W Ostrominski, Mats C Højbjerg Lassen, Brian L Claggett, et al.
European Journal of Heart Failure|March 15, 2024
Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant-level pooled analysis of DAPA-HF and DELIVERAlexander Peikert, Muthiah Vaduganathan, Brian L Claggett, et al.
Circulation. Heart Failure|August 7, 2026
MRAs and Race in Heart Failure: An Individual Participant Data Meta-Analysis of Randomized TrialsJawad H Butt, Pardeep S Jhund, Alasdair D Henderson, et al.
Journal of the American College of Cardiology|September 2, 2025
Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of Three Global TrialsJohn W Ostrominski, Josephine Harrington, Brian L Claggett, et al.
JAMA Cardiology|June 18, 2025
Finerenone According to Frailty in Heart Failure: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical TrialJawad H Butt, Pardeep S Jhund, Alasdair D Henderson, et al.
European Journal of Heart Failure|November 4, 2025
Finerenone in patients with severe heart failure: The FINEARTS-HF trialRiccardo M Inciardi, Henri Lu, Brian L Claggett, et al.
Pageof 36